Carregant...

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC). The quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sherrill, B, Amonkar, M M, Stein, S, Walker, M, Geyer, C, Cameron, D
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2528149/
https://ncbi.nlm.nih.gov/pubmed/18728660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604501
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!